Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

NSE/ZENITHDRUG stock hub

NSE/ZENITHDRUG has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NSE/ZENITHDRUGis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

698M

National Stock Exchange of India

Market data

Live price

Current market quote for this ticker.

Current price

NSE/ZENITHDRUG

In the news

Latest news · NSE/ZENITHDRUG

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 24.9P50 32.4P75 45.7

Trailing P/E18.5

P25 24.8P50 35.9P75 56.9

ROEn/a

P25 6.3P50 13.6P75 18.1

ROIC4.3

P25 4.1P50 10.3P75 17.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NSE/ZENITHDRUG market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

175

Groups with data

Currency

INR

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	India
Country code	IN
Employees	182
Employees Change	56%
Employees Change Percent	44.44
Enterprise value	INR 1.2B
Exchange	National Stock Exchange of India
Financial currency	INR
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	INE0QWN01013
Last refreshed	2026-05-10
Market cap	INR 698M
Price	INR 40.8
Price currency	INR
Rev Per Employee	7,903,774.73x
Sector	Healthcare
Sic	2834
Symbol	nse/ZENITHDRUG
Website	https://zenithdrugs.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	5.41%
EV Earnings	32.08x
EV/EBIT	14.62x
EV/EBITDA	8.91x
EV/Sales	0.84x
P/B ratio	0.97x
P/E ratio	18.5x
P/S ratio	0.49x
PE Ratio3 Y	19.34x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	5.76%
EBITDA Margin	9.46%
Gross margin	33.69%
Gross Profit	INR 484.6M
Gross Profit Growth	6.09%
Gross Profit Growth Q	7.08%
Gross Profit Growth3 Y	10.21%
Gross Profit Growth5 Y	32.44%
Net Income	INR 37.8M
Net Income Growth	-61.03%
Net Income Growth Q	-44.22%
Net Income Growth3 Y	-8.19%
Net Income Growth5 Y	27.2%
Pretax Margin	4.09%
Profit Margin	2.63%
Profit Per Employee	INR 207,549
Roa5y	6.85
ROCE	9.78
Roe5y	27.24
ROIC	4.33
Roic5y	16.25

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-49.75%
EPS Growth	30.42
EPS Growth Q	-27.58
EPS Growth3 Y	-18.53
EPS Growth5 Y	18.41
Revenue Growth	10.01x
Revenue Growth Q	25.74x
Revenue Growth3 Y	7.9x
Revenue Growth5 Y	22.48x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	INR 1.7B
Cash	INR 5M
Current Assets	INR 1.2B
Current Liabilities	INR 804.6M
Debt	INR 518.9M
Debt EBITDA	INR 3.81
Debt Equity	INR 0.72
Equity	INR 717.1M
Interest Coverage	2.38
Liabilities	INR 935.3M
Long Term Assets	INR 498.1M
Long Term Liabilities	INR 130.7M
Net Cash	INR -513.9M
Net Cash By Market Cap	INR -73.63
Net Debt EBITDA	INR 3.78
Net Debt Equity	INR 0.72
Tangible Book Value	INR 690.7M
Tangible Book Value Per Share	INR 40.22
WACC	8.73

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.43
Net Working Capital	INR 733M
Quick ratio	0.75
Working Capital	INR 349.8M
Working Capital Turnover	INR 3.42

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	70.12%
Dividend per share	INR 0
Last Dividend	INR 0.5

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-49.72%
200-day SMA	55.45
50-day SMA	42.91
50-day SMA vs 200-day SMA	50under200
All Time High	154.4
All Time High Change	-73.58%
All Time High Date	2024-09-26
All Time Low	33.3
All Time Low Change	22.52%
All Time Low Date	2026-03-30
ATR	2.25
Beta	1.41
Beta1y	0.98
Beta2y	0.4
Ch YTD	-18.73
High	43.25
High52	84.65
High52 Date	2025-05-13
High52ch	-51.8%
Low	39.8
Low52	33.3
Low52 Date	2026-03-30
Low52ch	22.52%
Ma50ch	-4.92%
Price vs 200-day SMA	-26.42%
RSI	45.41
RSI Monthly	37.89
RSI Weekly	37.26
Sharpe ratio	-1.07x
Sortino ratio	-1.45
Total Return	70.12%
Tr YTD	-18.73
Tr1m	1.12%
Tr1w	2.9%
Tr3m	-16.73%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	INR 82.9M
Operating Income Growth	-26.06
Operating Income Growth Q	-58.44
Operating Income Growth3 Y	-1.21
Operating Income Growth5 Y	26.83
Operating margin	5.76

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Shares Out	17,148,800
Shares Qo Q	-90.09%
Shares Yo Y	-70.12%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	5,720x
Bv Per Share	41.76
Ch1m	1.12
Ch1w	2.9
Ch1y	-49.72
Ch3m	-16.73
Ch6m	-35.39
Change	-5.01%
Change From Open	-4.9
Close	42.95
Days Gap	-0.12
Depreciation Amortization	53,172,500
Dollar Volume	750,720
Earnings Date	2026-05-29
EBIT	INR 82.9M
EBITDA	INR 136.1M
EPS	INR 2.2
F Score	1
Fiscal Year End	March
Founded	1,956
Graham Number	45.46228
Graham Upside	11.43
Income Tax	INR 21M
Is Primary Listing	1
Last Earnings Date	2026-02-13
Last Report Date	2025-09-30
Lynch Fair Value	INR 54.99
Lynch Upside	34.78
Ma150	51.01
Ma150ch	-20.02%
Ma20	42.59
Ma20ch	-4.2%
Next Earnings Date	2026-05-29
Open	42.9
Position In Range	28.99
Ppne	433,832,000
Price Date	2026-05-08
Price EBITDA	INR 5.13
Ptbv Ratio	1.01
Relative Volume	3.48x
Revenue	1,438,487,000x
Tax By Revenue	1.46x
Tax Rate	35.73%
Tr6m	-35.39%
Volume	18,400

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NSE/ZENITHDRUG pay a dividend?

Capital-return profile for this ticker.

Performance

NSE/ZENITHDRUG stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NSE/ZENITHDRUG?

Insider, institutional, and short-interest positioning.

Institutional ownership

n/a

Share of float held by funds and institutions

Insider ownership

n/a

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

-70.1%

Negative means the company is buying back shares.

Technical

NSE/ZENITHDRUG momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

45.4

Neutral momentum band

Price vs 200-day MA

-26.4%

50/200-day relationship not available

Beta (5Y)

1.41

More volatile than the market

Sharpe ratio

-1.07

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NSE/ZENITHDRUG

Hub-level FAQ points readers to the deeper analysis pages.

What is the current nse/ZENITHDRUG stock rating?

nse/ZENITHDRUG is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full nse/ZENITHDRUG analysis?

The full report lives at /stocks/nse/ZENITHDRUG/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for nse/ZENITHDRUG?

The latest report frames nse/ZENITHDRUG around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the nse/ZENITHDRUG page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.